安非他酮与喹硫平治疗双相情感障碍抑郁发作的临床疗效及安全性分析(1)
摘 要：目的 研究安非他酮与喹硫平治疗双相情感障碍抑郁发作的临床疗效及安全性。方法 选取2016年1月～2017年8月在我院治疗的双相情感障碍抑郁发作患者84例，随机分为安非他酮组和喹硫平组，每组42例。安非他酮组采取口服安非他酮治疗，喹硫平组采取口服喹硫平治疗，治疗2个月后观察对比两组患者临床治疗有效率、生活质量评分、抑郁症状改善时间、抑郁评分、不良反应发生情况。结果 喹硫平组治疗总有效率、生活质量评分高于安非他酮组，差异有统计学意义(P<0.05)；喹硫平组抑郁评分、不良反应发生率低于安非他酮组，且抑郁评分降低时间短于安非他酮组，差异有统计学意义(P<0.05)。结论 喹硫平治疗双相情感障碍抑郁发作的临床疗效理想，可显著改善患者临床症状，且不良反应少，用药安全性高，值得临床推广。
关键词：安非他酮；喹硫平；抑郁；安全性
中图分类号：R749.4 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.07.045
, 百拇医药
文章編号：1006-1959(2018)07-0134-03
Clinical Efficacy and Safety of Bupropion and Quetiapine in the Treatment of Bipolar Affective Disorder Depression
LI Hong-xin
(Department of Psychiatry，Anding Hospital，Jizhou District，Tianjin 301900，China)
Abstract：Objective To study the efficacy and safety of bupropion and quinalapine in the treatment of bipolar affective disorder depression.Methods From January 2016 to August 2017，84 patients with bipolar depression were randomly divided into two groups： acetophenone group(n=42)and quetiapine group(n=42).The bupropion group was treated with oral bupropion and the quetiapine group was treated with oral quetiapine.After 2 months of treatment，clinical efficacy，quality of life scores，time to improvement of depressive symptoms，and depression scores were observed and compared between the two groups，the occurrence of adverse reactions.Results Quetiapine treatment group total effective rate， quality of life score higher than the bupropion group，the difference was statistically significant(P<0.05)；occurrence of quetiapine group depression score，adverse reaction rate is lower than the bupropion group and depression scores decreased time shorter than the bupropion group，the difference was statistically significant(P<0.05).Conclusion The clinical efficacy of quetiapine in the treatment of depressive episodes of bipolar disorder is satisfactory.It can significantly improve the clinical symptoms of patients，and has fewer adverse reactions.The safety of medication is high and worthy of clinical promotion.
, 百拇医药
Key words：Bupropion；Quetiapine；Depression；Safety
双相情感障碍(bipolar disorder)是临床常见的一种慢性、容易复发的心境障碍疾病，同时伴有躁狂发作和抑郁发作反复间歇交替或循环发作性病程[1]。双相情感障碍患者抑郁发作更为多见，且发作时间较长。该疾病与单相抑郁相比较，双相障碍更易合并其他精神障碍及认知功能损害，给患者带来严重的心理负担。临床治疗双相情感障碍抑郁发作一直是难题，若治疗不合理可能导致转躁，所以临床寻找有效的治疗方法是当前迫切需要解决的问题之一。心境稳定剂目前是治疗双相障碍抑郁发作的基本用药[2]。随着第二代治疗药物的出现，也可实现心境稳定的作用，并且对双相情感障碍抑郁发作的急性期或维持治疗均有效。本文作者结合临床资料，对比研究安非他酮与喹硫平治疗双相情感障碍抑郁发作的临床疗效及安全性，现报告如下。
1资料与方法
1.1一般资料 选取2016年1月～2017年8月在天津市蓟州区安定医院治疗的84例双相情感障碍抑郁发作患者，依据随机数字表法分为安非他酮组和喹硫平组，每组42例。安非他酮组中，男22例，女20例；年龄22～60岁，平均年龄(30.10±7.55)岁；病程1～7年，平均病程(3.45±0.50)年。喹硫平组中，男21例，女21例；年龄20～61岁，平均年龄(29.62±0.20)岁；病程1～8年，平均病程(3.78±1.02)年。两组患者在性别、年龄、病程等基础资料方面，差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(李洪新)
关键词：安非他酮；喹硫平；抑郁；安全性
中图分类号：R749.4 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.07.045
, 百拇医药
文章編号：1006-1959(2018)07-0134-03
Clinical Efficacy and Safety of Bupropion and Quetiapine in the Treatment of Bipolar Affective Disorder Depression
LI Hong-xin
(Department of Psychiatry，Anding Hospital，Jizhou District，Tianjin 301900，China)
Abstract：Objective To study the efficacy and safety of bupropion and quinalapine in the treatment of bipolar affective disorder depression.Methods From January 2016 to August 2017，84 patients with bipolar depression were randomly divided into two groups： acetophenone group(n=42)and quetiapine group(n=42).The bupropion group was treated with oral bupropion and the quetiapine group was treated with oral quetiapine.After 2 months of treatment，clinical efficacy，quality of life scores，time to improvement of depressive symptoms，and depression scores were observed and compared between the two groups，the occurrence of adverse reactions.Results Quetiapine treatment group total effective rate， quality of life score higher than the bupropion group，the difference was statistically significant(P<0.05)；occurrence of quetiapine group depression score，adverse reaction rate is lower than the bupropion group and depression scores decreased time shorter than the bupropion group，the difference was statistically significant(P<0.05).Conclusion The clinical efficacy of quetiapine in the treatment of depressive episodes of bipolar disorder is satisfactory.It can significantly improve the clinical symptoms of patients，and has fewer adverse reactions.The safety of medication is high and worthy of clinical promotion.
, 百拇医药
Key words：Bupropion；Quetiapine；Depression；Safety
双相情感障碍(bipolar disorder)是临床常见的一种慢性、容易复发的心境障碍疾病，同时伴有躁狂发作和抑郁发作反复间歇交替或循环发作性病程[1]。双相情感障碍患者抑郁发作更为多见，且发作时间较长。该疾病与单相抑郁相比较，双相障碍更易合并其他精神障碍及认知功能损害，给患者带来严重的心理负担。临床治疗双相情感障碍抑郁发作一直是难题，若治疗不合理可能导致转躁，所以临床寻找有效的治疗方法是当前迫切需要解决的问题之一。心境稳定剂目前是治疗双相障碍抑郁发作的基本用药[2]。随着第二代治疗药物的出现，也可实现心境稳定的作用，并且对双相情感障碍抑郁发作的急性期或维持治疗均有效。本文作者结合临床资料，对比研究安非他酮与喹硫平治疗双相情感障碍抑郁发作的临床疗效及安全性，现报告如下。
1资料与方法
1.1一般资料 选取2016年1月～2017年8月在天津市蓟州区安定医院治疗的84例双相情感障碍抑郁发作患者，依据随机数字表法分为安非他酮组和喹硫平组，每组42例。安非他酮组中，男22例，女20例；年龄22～60岁，平均年龄(30.10±7.55)岁；病程1～7年，平均病程(3.45±0.50)年。喹硫平组中，男21例，女21例；年龄20～61岁，平均年龄(29.62±0.20)岁；病程1～8年，平均病程(3.78±1.02)年。两组患者在性别、年龄、病程等基础资料方面，差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(李洪新)